CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

The limited prognosis of patients with castration-resistant prostate cancer (CRPC) on existing hormonal manipulation therapies calls out for the urgent need for new management strategies. The novel, orally available, small-molecule compound, abiraterone acetate, is undergoing evaluation in early cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, J E, Olmos, D, de Bono, J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653756/
https://www.ncbi.nlm.nih.gov/pubmed/19223900
http://dx.doi.org/10.1038/sj.bjc.6604904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653756/
https://www.ncbi.nlm.nih.gov/pubmed/19223900
http://dx.doi.org/10.1038/sj.bjc.6604904

Ejemplares similares